0
iBio, Inc.: Item 5.02 filing
IBIO · Nasdaq · Pharmaceutical Preparations · Non-accelerated filer<br>Smaller reporting company · NY · Form 8-K filed 2026-10-19
No executive or director personnel changes reported in this Item 5.02 section.
Events in this filing
0 events: .
Names, stated reasons, successor status, compensation terms and the evidence quotes are shown to subscribers. See plans
Item 5.02 as filed
Item 5.02 and in the Definitive Proxy Statement. The results of the voting for this approved proposal are as follows: Votes For Votes Against Abstentions Broker Non-Votes 27,693,575 8,263,100 226,837 12,060,752 Proposal 6 - Adjournment Proposal The stockholders approved the adjournment of the Annual Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there were not sufficient votes in favor of Authorized Share Increase Proposal and/or the Plan Amendment Proposal, as described in the Definitive Proxy Statement. The results of the voting for this approved proposal are as follows: Votes For Votes Against Abstentions Broker Non-Votes 27,867,928 8,100,316 215,268 12,060,752 Notwithstanding the approval of this proposal, because each of the Authorized Share Increase Proposal and the Plan Amendment Proposal received the requisite votes for approval at the Annual Meeting as convened, it was not necessary for the Company to adjourn the Annual Meeting. Source filing on EDGAR →